Best Practice & Research Clinical Haematology

Papers
(The median citation count of Best Practice & Research Clinical Haematology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Contemporary and future strategies in polycythemia vera55
The role of randomized controlled trials, registries, observational databases in evaluating new interventions24
HLA typing: A review of methodologies and clinical impact on haematopoietic cell transplantation22
Asparaginase dosing for obese patients with acute lymphoblastic leukemia and factors that contribute to outcomes21
Endpoint selection and evaluation in hematology studies18
Coagulopathy in COVID-19 and anticoagulation clinical trials18
“The state of the science” of childhood, adolescent and young adult Non Hodgkin Lymphoma (NHL)17
What are the long-term complications of pediatric ALL treatments and how can they be mitigated? Perspectives on long-term consequences of curative treatment in childhood ALL17
Allogeneic “Off-the-Shelf” CAR T cells: Challenges and advances14
Reducing barriers of access and care related to hematopoietic cell transplantation and cellular therapy: The mission-driven role of the national marrow donor program14
Advances in CAR design13
The presentation of results from studies in clinical haematology13
Editorial Board13
Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults13
Take a spin: Apheresis in the care of adult leukaemia patients13
Creating a GMP cell processing program: A focus on quality and regulation12
Vaccine-induced immune thrombotic thrombocytopenia12
Blood coagulation and cancer genes11
Biopathology of childhood, adolescent and young adult non-Hodgkin lymphoma11
How can we improve response assessments in MDS? Strategies to improve response assessment in MDS treatment paradigms10
Targeted cellular therapy for treatment of relapsed or refractory leukemia10
Accelerated and blast phase myeloproliferative neoplasms10
Principles of cost-effectiveness studies and their use in haematology9
Cancer associated thrombosis in pediatric patients9
Cytogenomics of B-cell non-Hodgkin lymphomas: The “old” meets the “new”9
Dysregulation of Protein S in COVID-199
What should be done and what should be avoided when comparing two treatments?9
The international cooperative Gaucher group (ICCG) Gaucher registry9
Editorial Board8
Applications and prospects of molecularly targeted drugs combined with CAR-T cell therapy to treat multiple myeloma8
Is HLA-E with its receptors an immune checkpoint or an antigenic determinant in allo-HCT?7
Late effects and frontline treatment selection for children with non-Hodgkin lymphoma7
Worldwide sources of data in haematology: Importance of clinician-biostatistician collaboration7
Clinical experience of CAR T cells for multiple myeloma7
Addressing symptom burden in myeloproliferative neoplasms7
Prevention and treatment of COVID-19 in patients with benign and malignant blood disorders7
The role of registries in hematological disorders7
Handling missing covariate data in clinical studies in haematology6
Human mesenchymal stem cell therapy: Potential advances for reducing cystic fibrosis infection and organ inflammation6
The analysis of multiple outcomes, multiple variables and variables selection in hematopoietic cell transplantation studies6
Hodgkin Lymphoma: A disease shaped by the tumor micro- and macroenvironment6
Thrombosis and bleeding in hematological malignancy6
Anti-GM-CSF autoantibodies in myeloid leukemias6
How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?6
CAR assembly line: Taking CAR T-cell manufacturing to the next level5
Cytokines in hematopoietic cell transplantation and related cellular therapies5
Recent progress in acute leukemia and myelodysplasia5
Advances in polycythemia vera and lessons for acute leukemia5
Challenges in anticoagulation for patients with brain tumors5
What is the role of the bone marrow microenvironment in AML?5
A reflection on Arnold Caplan, the father of MSC5
Editorial Board / Aims & Scope5
Preface5
The current landscape: Allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia5
Cytogenetics and genomics in CML and other myeloproliferative neoplasms4
The most frequent HLA alleles around the world: A fundamental synopsis4
Relevance of donor-specific HLA antibodies in hematopoietic cell transplantation4
SARS-CoV-2 primary and breakthrough infections in patients with cancer: Implications for patient care4
Corrigendum to “Endpoint selection and evaluation in hematology studies” [Best Pract Res Clin Haematol 36 (2023) 101479]4
What is relative survival and what is its role in haematology?4
Corrigendum to “Designing and conducting a clinical trial in blood and marrow transplantation” [Best Pract Res Clin Haematol 36 (2023) 101471]4
When to use which molecular prognostic scoring system in the management of patients with MDS?3
Shape of the art: TCR-repertoire after allogeneic hematopoietic cell transplantation3
Mesenchymal stem cells in hematology: Therapeutic initiatives and future directions3
Editorial Board / Aims & Scope3
COVID-19 and antiphospholipid antibodies3
Clinical experience of CAR T cell therapy in lymphomas3
Donor lymphocyte infusion in Acute Myeloid Leukemia3
CARs for lymphoma3
Diagnosis and management of rare paediatric Non-Hodgkin lymphoma3
Interfering with KIR and NKG2A immune checkpoint axes to unleash NK cell immunotherapy3
Diagnosis and management of mature B-cell lymphomas in children, adolescents, and young adults3
Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemia3
Preface of special edition “Biostatistics in clinical haematology”3
The correlations among racial/ethnic groups, hypertriglyceridemia, thrombosis, and mortality in hospitalized patients with COVID-193
Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents3
Cytokine therapy of acute radiation syndrome3
Considerations to comprehensive care for the older individual with myelofibrosis3
Using real-world evidence in haematology2
Can venetoclax-based therapy replace 7+3 induction in fit older adults with AML?2
The best GVHD prophylaxis: Or at least progress towards finding it2
Designing and conducting a clinical trial in blood and marrow transplantation2
Since everyone has a donor, why are some eligible patients still not transplanted?2
Is there an optimal adjunct therapy to traditional cytotoxic induction?2
Germline predisposition to myeloid neoplasms: Characteristics and management of high versus variable penetrance disorders2
COVID-19: A hematological perspective2
Consolidation chemotherapy in AML: Are we playing with a full deck of cards?2
Editorial Board / Aims & Scope2
The Collaborative Biobank (CoBi): Donor and recipient samples & data to facilitate future research on hematopoietic cell transplantation2
Thromboprophylaxis of cancer patients undergoing systemic therapy in the ambulatory setting2
Redox stress in COVID-19: Implications for hematologic disorders2
Deciphering the role of the major histocompatibility complex, the intestinal microbiome and metabolites in the pathogenesis of acute graft-versus-host disease1
The history of cytokines and growth factors development1
Progress and challenges in the acute leukemia field1
Allogeneic hematopoietic cell transplantation in acute myeloid leukemia1
Effectiveness of allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia1
Advancing MSC therapy: The next generation of potent mesenchymal stromal cells for systemic autoimmune rheumatic diseases1
Clinical experience of CAR T cells for B cell acute lymphoblastic leukemia1
Has Ph-like ALL Superseded Ph+ ALL as the Least Favorable Subtype?1
WHO, what, when, where, and why: New classification systems for acute myeloid leukemia and their impact on clinical practice1
Toxicities associated with adoptive cellular therapies1
Transplantation algorithm for myelofibrosis in 2022 and beyond1
Editorial Board1
Graft versus Leukemia in 20231
Cytogenetics in haematology1
Myeloproliferative neoplasms in adolescents and young adults1
Immunopathogenic mechanisms and modulatory approaches to graft-versus-host disease prevention in acute myeloid leukaemia1
Editorial Board1
Important factors improving outcome of young adults with acute lymphoblastic leukemia (ALL)1
Analyte heterogeneity analysis as a possible potency parameter for MSC1
Research progress of targeted BCMA CAR-T therapy for relapsed/refractory multiple myeloma antigen-negative relapse1
Current status of pretransplant intensive chemotherapy or hypomethylating agents for myelodysplastic syndrome1
New targets for CAR T therapy in hematologic malignancies1
Measurable residual disease in acute lymphoblastic leukemia: How low is low enough?1
Cytogenetics and genomics of acute myeloid leukemia1
Minor histocompatibility antigens to predict, monitor or manipulate GvL and GvHD after allogeneic hematopoietic cell transplantation1
HLA-DM and HLA-DO interplay for the peptide editing of HLA class II in healthy tissues and leukemia1
The Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes Registry1
Diagnosis and management of Hodgkin lymphoma in children, adolescents, and young adults1
Cytokines in transplantation tolerance1
Cytogenetics and genomics in pediatric acute lymphoblastic leukaemia1
How can we intervene to mitigate post-transplantation relapse in AML? Strategies to mitigate post-transplantation relapse in AML1
0.038332939147949